Botulinum toxin A - Merz Pharma
Alternative Names: Bocouture; Incobotulinum toxin A; NT 201L; NT-201; Xeomeen; XEOMIN; Xeomin; Xeomin cosmetic; ZeomaineLatest Information Update: 19 Jun 2024
At a glance
- Originator BIOTECON Therapeutics
- Developer Merz Aesthetics; Merz Pharma; Merz Pharmaceuticals GmbH; Yale University
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Blepharospasm; Dystonia; Glabellar lines; Muscle spasticity; Sialorrhoea; Torticollis
- Phase III Atrial fibrillation; Facial wrinkles
- Phase II Alopecia; Essential tremor; Pain; Skin aging; Trigeminal neuralgia
- Phase I Unspecified
- Discontinued Cancer pain
Most Recent Events
- 14 Jun 2024 Swissmedic approves incobotulinumtoxinA for treatment of lower limb Muscle spasticity in Switzerland
- 24 Jan 2024 Merz Aesthetics completes the phase-II PAOLA trial in Skin aging (Platysma Prominence) in USA (IM) (NCT05773053)
- 22 Nov 2023 Launched for Sialorrhoea (In children, In adults) in Australia (IM)